ibrutinib

Overview

Covalent BTK inhibitor; standard-of-care in CLL and other B-cell malignancies.

Evidence in the corpus

• In the 1,148-patient CLL map, TP53 mutation in the absence of 17p deletion was not associated with adverse outcomes in U-CLL, consistent with the modern ibrutinib/venetoclax era reducing the prognostic impact of isolated TP53 mutation PMID:35927489.

Resistance mechanisms

• Not directly characterized in this corpus; the paper cites the ibrutinib era as attenuating TP53-alone adverse prognosis PMID:35927489.

Cancer types (linked)

• CLLSLL

Sources

• PMID:35927489

This page was processed by crosslinker on 2026-04-09.